Unum Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the developing and commercializing of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is used in combination with a range of tumor-specific antibodies to target different tumor types. The Company's product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development. The ACTR platform to transform cancer treatment and deliver patient cures in many different hematologic and solid tumor cancers, improving upon current cell therapies. The Company's product pipeline that includes clinical stage product candidates: ACTR087, ACTR087 (SEA-BCMA) and ACTR707.